Another study has been published suggesting that patients taking semaglutide—the active ingredient in Novo Nordisk’s blockbuster drug Ozempic—may face a higher risk of developing a rare eye condition that can lead to blindness.

“The glucagon-like peptide 1 receptor agonist (GLP-1RA) semaglutide has quickly become a key treatment for managing type 2 diabetes and obesity. Recent findings have raised concern about a potential association between semaglutide use and non-arteritic anterior ischemic optic neuropathy (NAION),” according to a new Danish–Norwegian study, backing up similar results from a Harvard University study published in July.

https://discernreport.com/new-study-links-ozempic-to-vision-loss-confirms-harvard-research/